Clinical Trial Update: Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating rituximab for systemic sclerosis-associated pulmonary arterial hypertension has completed; results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Sclerosis-associated Pulmonary Arterial Hypertension

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Systemic Sclerosis-Associated PAH | Phase 2 | Status: COMPLETED | Results posted: 2020-08-21